Clinical Trials

REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.

This clinical trial will have 2 components: a brief dose-ranging study and a randomized comparison of 2 doses of AdKCNH2-G628S with control cardiac surgery patients. The study will assess safety of the intervention in a population at increased risk for post-operative atrial fibrillation.

Do you know someone who will be having heart surgery? This study aims to identify what genetic patterns might cause atrial fibrillation and other adverse events that happen after heart surgery. To participate in this study, you must be between 20 and 90 years old. The study is in three locations in Massachusetts and Texas.

Did you develop atrial fibrillation after coronary artery bypass graft (CABG) surgery? Did you develop atrial fibrillation after a coronary artery bypass grafting (CABG) surgery? This study is looking at how well oral anticoagulation medicines work to prevent complications, such as blood clots and heart attack, for patients who experience post-operative atrial fibrillation (POAF). This study is in multiple locations around the country.

Are you an adult planning to have heart surgery at Brigham and Women’s Hospital or Texas Heart Institute? This study is looking into the genetic causes of heart problems that can happen after heart surgery, such as atrial fibrillation, myocardial infarction, renal dysfunction, and heart failure. To participate in this study, you must be between 20 and 90 years old. This study takes place in Boston, Massachusetts; and Dallas and Houston, Texas.

The MIDAS study aims to follow LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.

Are you an adult woman who would like to help develop methods to prevent the worsening of LAM? This study aims to discover whether earlier and longer treatment with a lower dose of sirolimus can help prevent LAM from getting worse over time. To participate in this study, you must be female, be at least 18 years old, and have been diagnosed with LAM. This study is located in Atlanta, Georgia; Boston, Massachusetts; Chicago, Illinois; Cincinnati, Ohio; Denver, Colorado; Nashville, Tennessee; Palo Alto, California; Philadelphia, Pennsylvania; and Seattle, Washington.

Does your infant have a low platelet count? This study is investigating the safety and efficacy of platelet transfusion as a treatment for infants with thrombocytopenia. Researchers are looking at the positive effects of platelet transfusion against the negative effects, such as the release of inflammatory molecules and the formation of blood clots. To participate in this study, your child must be younger than 6 months old and have a low platelet count (less than 100 × 109/L). This study takes place in Boston, Massachusetts.

Does your infant have a low platelet count? This study investigates immature platelet counts as a marker for bleeding risk in newborns with thrombocytopenia, compared with platelet counts alone. Immature platelets are the most recently produced platelets and may be a better marker of platelet production. To participate in this study, you must have a newborn who is less than 32 weeks’ gestational age, has a birth weight greater than 500 grams, and has a platelet count less than 100 × 109/L. This study takes place in multiple locations in the United States, the Netherlands, and Sweden.